Home › Funds › Hood River Capital Management LLC › PTGX
Hood River Capital Management LLC position in PTGX
PROTAGONIST THERAPEUTICS INC · Health Care
Hood River Capital Management LLC reported holding 893,479 shares of PTGX (PROTAGONIST THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$125.9M, representing 1.07% of its reported portfolio and ranking #26 among its reported holdings. Hood River Capital Management LLC has disclosed PTGX holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Hood River Capital Management LLC's PTGX position evolved
Hood River Capital Management LLC first disclosed a stake in PTGX in Q1 2026 at 829,285 shares (US$87.4M). The position peaked in Q3 2026 at 893,479 shares, worth US$125.9M. Across 3 filings, Hood River Capital Management LLC increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 893,479 shares valued at US$125.9M — an increase of 10,741 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 829.28K | $87.41M | New |
| Q2 2026 | 882.74K | $108.21M | Add |
| Q3 2026 | 893.48K | $125.88M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PTGX and 13F data
PTGX (PROTAGONIST THERAPEUTICS INC) is a Health Care company. 48 other funds we track also report a position in PTGX — the largest reported positions include FARALLON CAPITAL MANAGEMENT, L.L.C. (US$907.0M), Farallon Capital Management (US$778.2M), RTW INVESTMENTS, LP (US$713.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PTGX
- FARALLON CAPITAL MANAGEMENT, L.L.C. 6.44M sh · $907.04M · Q3 2026
- Farallon Capital Management 6.35M sh · $778.25M · Q2 2026
- RTW INVESTMENTS, LP 5.06M sh · $713.07M · Q3 2026
- JOHNSON & JOHNSON 2.45M sh · $345.07M · Q3 2026
- Woodline Partners LP 1.41M sh · $198.59M · Q3 2026
- ADAR1 Capital Management, LLC 951.40K sh · $134.04M · Q3 2026
- PERCEPTIVE ADVISORS LLC 981.88K sh · $120.36M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 676.82K sh · $95.36M · Q3 2026
- 683 Capital Management, LLC 255.00K sh · $35.93M · Q3 2026
- Eagle Health Investments LP 248.32K sh · $34.99M · Q3 2026
More on Hood River Capital Management LLC
FAQ
How long has Hood River Capital Management LLC held PTGX?
Hood River Capital Management LLC has disclosed PTGX holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Hood River Capital Management LLC's current position in PTGX?
As of Q3 2026, Hood River Capital Management LLC holds 893.48K shares of PTGX (PROTAGONIST THERAPEUTICS INC), valued at $125.88M, representing 1.07% of its reported portfolio and ranking #26.
Has Hood River Capital Management LLC been buying or selling PTGX?
In the latest 13F filing (Q3 2026), Hood River Capital Management LLC increased its position in PTGX. The position peaked in Q3 2026 at 893.48K shares.
Which other funds hold PTGX?
Other major institutional holders of PTGX include FARALLON CAPITAL MANAGEMENT, L.L.C., Farallon Capital Management, RTW INVESTMENTS, LP, among 48 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.